ReLIA completes the Pre-IPO round of financing !

On April 24, ReLIA announced that it had completed hundreds of millions of yuan of Pre-IPO equity financing in April 2020.


ReLIA was established in 2001, the basic research and development center was established in Silicon Valley, and the Asia-Pacific headquarters was located in Shenzhen Shekou Free Trade Zone. At present, the company has large-scale R&D centers and production bases in Shenzhen and Taizhou, Jiangsu. The company's founder, Dr. Willian J. Rutter, is a well-known entrepreneur in the field of precision medicine in the United States. He has served as a senior executive and technical consultant for Novartis, Abbott and other companies; Ms Libby Xu, general manager, was the POC leader of Abbott China, and Liu Jianyuan, the factory leader, participated in SARS Etiology and air defense series of research, won the National Science and Technology Progress Award.


POCT (point-of-care testing) is currently the fastest growing field of laboratory medicine. Fast and accurate detection methods can enable patients to be diagnosed and treated as soon as possible. ReLIA specializes in the research, development, production and sales of POCT rapid diagnostic equipment and supporting detection reagents. The company has two large platform bedside rapid detection systems: Multifunctional Immunoassay System and Immunofluorescence  System. The testing items cover cardiovascular disease diagnosis, kidney injury disease diagnosis and infection and inflammation disease diagnosis, with more than 20 domestic and foreign patents and more than 50 product certificates. ReLIA is comparable to international leading companies in terms of detection product accuracy and other technical indicators, and is at the leading level of domestic enterprises. The potential for import substitution in the top three domestic hospitals is huge. ReLIA has established a strong distribution network, covering a broad domestic market and a highly potential international market.


Based on an advanced R&D technology platform, ReLIA quickly launched new rapid detection reagents for coronavirus during this outbreak. The company's POCT equipment and detection reagent cards have been widely praised by first-line medical staff in Wuhan Huoshenshan Hospital and other important anti-epidemic front lines because of their advantages of fast, accurate, portable, and avoiding cross infection. At present, some products of Ruilai Bio have obtained EU certification. After the completion of this round of financing, Ruilai Bio will further expand its production capacity to meet the needs of more domestic and foreign customers.


ReLIA will continue to uphold the founder's philosophy: provide fast and accurate diagnostic services for human health, create the most valuable POCT products, provide high-quality, reliable products and services, and benefit the world!

Copyright © 2018 ReLIA Biological Engineering (Shanghai) Co., Ltd. All rights reserved

After Sales Service